Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial
| Autor: | Annagiulia Gramenzi, Mauro Bernardi, L. Di Giammarino, Stefania Lorenzini, Silvia Galli, Carmela Cursaro, Federica Porzio, Sirio Fiorino, F. Felline, Pietro Andreone, Maurizio Biselli, Elisabetta Loggi |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Ketoprofen
Adult Male medicine.medical_specialty Alpha interferon Interferon alpha-2 Gastroenterology Antiviral Agents Severity of Illness Index Drug Administration Schedule law.invention chemistry.chemical_compound Randomized controlled trial law Interferon Reference Values Virology Internal medicine medicine Humans Adverse effect Probability Chi-Square Distribution Hepatology Dose-Response Relationship Drug business.industry Ribavirin Standard treatment Incidence (epidemiology) Anti-Inflammatory Agents Non-Steroidal Interferon-alpha Hepatitis C Chronic Middle Aged Recombinant Proteins Surgery Infectious Diseases Treatment Outcome chemistry Drug Therapy Combination Female business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of viral hepatitis. 10(4) |
| ISSN: | 1352-0504 |
| Popis: | In this randomized controlled study, we evaluated the efficacy and safety of interferon-alpha combined with ketoprofen to that of interferon-alpha alone in naive patients with chronic hepatitis C. Forty patients were randomized to receive Interferon-alpha2a (3 million units three times a week) and ketoprofen (150 mg twice a day) and 40 to receive only interferon-alpha2a at the same dose. Patients were treated for 6 months and followed up for 6 months. Response was defined by undetectable HCV-RNA in serum at the end-of-treatment and after 6 months from the completion of therapy (long term response). At the end of treatment the response was similar in the two group. However, combination treatment showed significantly higher efficacy than monotherapy in achieving long term response (10%vs 32.5%; P = 0.014). Overall adverse events were similar in the two groups. 'Flu-like syndrome was significantly less common in the ketoprofen plus interferon group which experienced a significantly higher incidence of epigastric pain'. Our results indicate that the combination of ketoprofen plus interferon is significantly more effective than interferon alone in the treatment of naive patients with chronic hepatitis C and is well tolerated. However this combined treatment appears to be less effective than the association of pegylated IFN and ribavirin which represent the current standard treatment. Thus, the role of ketoprofen in the treatment of chronic hepatitis C needs to be further evaluated against such a treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text